Table 1.
Core study baseline characteristics of early relapsers and early non-relapsers.
| Parameters | CARE-MS I |
CARE-MS II |
||
|---|---|---|---|---|
| Early Relapsers (n = 56) | Early Non-relapsers (n = 320) | Early Relapsers (n = 105) | Early Non-relapsers (n = 330) | |
| Age, years, mean (SD) | 33.6 (7.4) | 32.9 (8.2) | 34.6 (8.8) | 34.8 (8.2) |
| Female, n (%) | 43 (77) | 200 (63)a | 77 (73) | 210 (64) |
| White, n (%) | 49 (88) | 303 (95) | 96 (91) | 296 (90) |
| EDSS score, mean (SD) | 2.3 (0.7) | 2.0 (0.8)a | 3.0 (1.4) | 2.6 (1.2)a |
| Years since the initial clinical attack, mean (SD) | 1.7 (1.2) | 2.2 (1.4) | 4.3 (2.7) | 4.5 (2.7) |
| Years since the last relapse, mean (SD) | 0.3 (0.2) | 0.4 (0.2) | 0.4 (0.2) | 0.4 (0.2) |
| No. of relapses in prior 1 year, mean (SD) | 2.18 (0.90) | 1.69 (0.78)a | 1.85 (0.90) | 1.60 (0.85)a |
| No. of relapses in prior 2 years, mean (SD) | 2.91 (0.88) | 2.45 (0.83)a | 3.14 (1.37) | 2.65 (1.10)a |
| Gd-enhancing lesion count, mean (SD) | 2.4 (4.5) | 2.3 (5.2) | 1.6 (3.1) | 2.5 (6.7) |
| Patients with Gd-enhancing lesions, n (%) | 25 (44.6) | 146 (46.3) | 41 (39.0) | 140 (43.2) |
| BPF, mean (SD) | 0.82 (0.02) | 0.82 (0.02) | 0.82 (0.02) | 0.81 (0.02) |
BPF: brain parenchymal fraction; CARE-MS: Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis; EDSS: Expanded Disability Status Scale; Gd: gadolinium; SD: standard deviation.
a
A value of p < 0.05 versus early non-relapsers (based on Wilcoxon rank-sum test or chi-square test).